Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Un Approccio di Medicina di Precisione Per Valutare la Perdita di Funzione Proteica e il Potenziale Recupero di CFTR in Fibrosi Cistica e Patologie Correlate / A Precision Medicine Approach to Assess Protein Function Loss and the Potential for CFTR Function Restoration in Cystic Fibrosis and Related Disorders

NCT07889973 is registered in ClinicalTrials.gov with Istituto Giannina Gaslini as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07889973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Un Approccio di Medicina di Precisione Per Valutare la Perdita di Funzione Proteica e il Potenziale Recupero di CFTR in Fibrosi Cistica e Patologie Correlate / A Precision Medicine Approach to Assess Protein Function Loss and the Potential for CFTR Function Restoration in Cystic Fibrosis and Related Disorders
Lead sponsor
Istituto Giannina Gaslini
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2024
Completion date
December 31, 2026
Enrollment
165 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf)

Arms

As registered; 4 arms.

  • Patients with cystic fibrosis

    Patients with cystic fibrosis

  • children with CFSPID

    children with CFSPID

  • patients with idiopathic bronchiectasis

    patients with idiopathic bronchiectasis

  • Patients with CFTR-related disorder

    Patients with CFTR-related disorder

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Molecular and Functional Characterization through study completion, an average of 2 years

    Molecular and Functional Characterization of CFTR Orphan Variants and Their Responsiveness to CFTR Modulator Therapies in Patients with Cystic Fibrosis (CF)

Lead sponsor's other trials

Istituto Giannina Gaslini, most recent start first.

Similar trials

Same condition (Cystic Fibrosis) and phase, most recent start first.